Jnpc Pharma Innovation Limited - Due diligence report

A 360° intelligence report on Jnpc Pharma Innovation Limited: trust score, financial health, credit view, compliance, directors, growth and …

2011-11-23 Hyderabad, Telangana Active Unlisted Active Compliant
Share
JP Jnpc Pharma Innovation Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Jnpc Pharma Innovation Limited — 360° Intelligence Report

Generated from MCA filings & public records
82/100
Trust Score
Low Risk

Jnpc Pharma Innovation Limited is assessed as Low Risk with a Trust Score of 82/100. Jnpc Pharma Innovation Limited is an active public limited indian non-government company incorporated in 2011, operating in the Pharma sector. Processed financial statements are not yet available for trend analysis. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 16 Jul 2026 from the latest processed filings. Jnpc Pharma Innovation Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
82/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
45/100
Board strength, DIN status, churn and network.
Growth ScoreNo Data
N/A
Needs at least two filed years to measure growth.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 1 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 93/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 45/100
NameDIN / PANDesignationAppointedTenureDIN status
YANCHARLA RATHNAKARA NAGARAJA 01234567 Director 01/04/2018 6 yrs Approved
POPURI PANDARI LAL KRISHNA 01234567 Director 01/04/2018 6 yrs Approved
PAKANATI VENKATA RAGHAVA REDDY 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • PAKANATI VENKATA RAGHAVA REDDY has DIN status "Disqualified by RoC u/s 164(2)".
  • 2 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2017 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Ramky Pharma City (india) Limited
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Ramky Pharma City (india) Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth N/A · Distress 90
Growth signals & trust indicators
Operating for 14+ years.
Distress signals & risk flags
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence89/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment88/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view48/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 15 events
10 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
06 Sep 2024
Director ceased
PAKANATI VENKATA RAGHAVA REDDY
05 Feb 2024
Director appointed
PAKANATI VENKATA RAGHAVA REDDY (Director)
29 Sep 2023
Director ceased
AJAY KUMAR MASAND
30 Sep 2021
Director ceased
YANCHARLA RATHNAKARA NAGARAJA
03 Jul 2021
Director appointed
YANCHARLA RATHNAKARA NAGARAJA (Director)
Director ceased
SRIDHAR REDDY MANDADI
25 Sep 2017
Director ceased
DIVAKAR MARRI
16 Feb 2017
Director ceased
GOUTHAM REDDY MAREDDY
30 Sep 2013
Director ceased
POPURI PANDARI LAL KRISHNA
21 Jan 2013
Director appointed
POPURI PANDARI LAL KRISHNA (Director)
Director ceased
RADHEY SHYAM GARG
Director ceased
SREESHA ATTUR
03 Sep 2012
Director ceased
YOGANJANEYA REDDY PANEM
10

Key Observations

Auto-generated from the data above
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); review board churn before relying on management continuity.
Promoters hold a dominant controlling stake as per the FY 2017 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Ramky Food Park (Chattisgarh) Limited U45209CT2007PLC020373 Raipur, Chattisgarh, India
Taurionzeus Structures And Technologies Private Limited U51100MH2013PTC244837 Nagpur, Maharashtra, India
R.K.R Builders And Promoters Private Limited U45200TG2002PTC040056 Hyderabad, Telangana, India
Samrat Engicon Limited U45200BR2016PLC025720 Gaya, Bihar, India
Star Infra Powercom Private Limited U45400DL2014PTC263643 Delhi, Delhi, India
Ashva Infrastructure & Engineering Private Limited U45204DL2011PTC212280 New Delhi, Delhi, India
Meson Engineering Private Limited U45201UP2014PTC065012 Ghaziabad, Uttar Pradesh, India
Psvr Constructions Private Limited U45400TG2015PTC101074 Hyderabad, Telangana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Jnpc Pharma Innovation Limited before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Jnpc Pharma Innovation Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score n/a, margin trends, ownership structure and peer set for Jnpc Pharma Innovation Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 82/100, distress signals and MSME payment-delay disclosures - know whether Jnpc Pharma Innovation Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Jnpc Pharma Innovation Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Jnpc Pharma Innovation Limited an active company?

Jnpc Pharma Innovation Limited has MCA status “Active” with a compliance score of 93/100 (Low Risk).

Is Jnpc Pharma Innovation Limited financially healthy?

Jnpc Pharma Innovation Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Jnpc Pharma Innovation Limited?

Its overall Trust Score is 82/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Jnpc Pharma Innovation Limited?

The ultimate holding entity is Ramky Pharma City (india) Limited. 3 active director(s) are on record.

Does Jnpc Pharma Innovation Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Jnpc Pharma Innovation Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).

Is it risky to lend to Jnpc Pharma Innovation Limited?

Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.